CLM-202 / CellabMed - LARVOL DELTA

Revolutionizing solid tumor treatment : Viral protein-targeted CAR-T with oncolytic virus (AACR 2024) - "In summary, our research proposes a novel therapeutic strategy, CLM-202 that utilizes NDV F CAR-T and NDV to overcome the limitations of CAR-T cell therapy in solid tumors, including tumor heterogeneity and immune-suppressive tumor microenvironments. This approach aims to effectively treat a wide range of indications."

IO biomarker • Oncolytic virus • Oncology • Solid Tumor

CellabMed announces non-clinical results of HESED-based ’CLM-202’ at AACR [Google translation] (HIT News) - "CellabMed...will report the results of non-clinical research on its HESED-based 'CLM-202 (development code name)' from the 5th to the 10th of next month (local time). It was announced on the 18th that it will be unveiled at the American Association for Cancer Research (AACR 2024) held in San Diego, USA...HESED infects cancer cells with an anti-cancer virus that expresses a specific target molecule and delivers the target so that CAR-T can recognize the cancer cell. At the same time, it changes the tumor microenvironment to be CAR-T friendly and then creates a CAR-T that recognizes the specific target molecule....'We confirmed that CLM-202, based on HESED, can effectively kill various cancer cell lines such as glioblastoma, triple-negative breast cancer, and pancreatic cancer that do not have common cancer-specific antigens,' and 'glioblastoma orthotopic transplant animals.'"

Preclinical • Brain Cancer • Breast Cancer • CNS Tumor • Gastrointestinal Cancer • Glioblastoma • Oncology • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer